In obesity medicine, this refers to a drug that stimulates the GLP-1, GIP, and glucagon receptors to manage appetite, improve insulin sensitivity, and raise metabolic energy expenditure
Tirzepatide (weekly injectable) Dosing frequency: Once weekly, same day each week Half-life: approximately 5 days (120 hours) Peak concentration: 8 to 72 hours after injection Recommended timing approach: The shorter half-life compared to semaglutide means the end-of-week trough is more noticeable
GIPR agonism in the context of a functioning GLP-1R signal produces synergistic effects that neither pathway achieves alone
About the practical aspects: "What is the titration schedule, and how quickly will we increase the dose?" "How should I handle injection technique and site selection ?" "What is the best time of day to take this medication?" "How should I store the medication ?" "What happens if I miss a dose or need to adjust timing ?" Practical questions demonstrate that you are already thinking about adherence and implementation, not just acquisition
This precise control minimizes energy dips and cravings for high-calorie foods
.png)
